The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical and technical validation of a genomic classifier (ColoPrint) for predicting outcome of patients with stage II colon cancer.
Josep Tabernero
No relevant relationships to disclose
Victor Moreno
No relevant relationships to disclose
Robert Rosenberg
Other Remuneration - Agendia
Ulrich Nitsche
No relevant relationships to disclose
Thomas Bachleitner-Hofmann
No relevant relationships to disclose
Giovanni Lanza
No relevant relationships to disclose
Jeroen van den Akker
Employment or Leadership Position - Agendia
Paul Roepman
Employment or Leadership Position - Agendia
Stock Ownership - Agendia
Iris Simon
Employment or Leadership Position - Agendia
Ramon Salazar
Other Remuneration - Agendia